Advertisement
Screener

SERA PROGNOSTICS, INC. (SERA) Professional Fees

2.8 / 5 stars · 68/120 Roast Me

SERA PROGNOSTICS, INC. Professional Fees

SERA PROGNOSTICS, INC. (SERA) reported Professional Fees of $1.64 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.

Financial Statements › Expense Statement › Operating Expenses

us-gaap:ProfessionalFees · last filed 2026-08-12

  • SERA PROGNOSTICS, INC. professional fees for the quarter ending 2026-06-30 was $1.64M, a 19.64% decline year-over-year.
  • SERA PROGNOSTICS, INC. professional fees for the quarter ending 2026-03-31 was $1.92M, a 4.91% increase year-over-year.
  • SERA PROGNOSTICS, INC. professional fees for the quarter ending 2025-12-31 was $1.55M, a 37.42% decline year-over-year.
  • SERA PROGNOSTICS, INC. professional fees for the quarter ending 2025-09-30 was $1.51M, a 14.17% decline year-over-year.
  • SERA PROGNOSTICS, INC. professional fees for fiscal 2025 was $6.94M, a 8.40% decline from fiscal 2024.
  • SERA PROGNOSTICS, INC. professional fees for fiscal 2024 was $7.58M, a 51.26% increase from fiscal 2023.
  • SERA PROGNOSTICS, INC. professional fees for fiscal 2023 was $5.01M.
Period endProfessional Fees 3 monthProfessional Fees 6 monthProfessional Fees 9 monthProfessional Fees 12 month
2026-06-30$1.64M
10-Q · filed 2026-08-12
$3.56M
10-Q · filed 2026-08-12
$5.12M
derived: sum of 3 quarters · filed 2026-08-12
$6.63M
derived: sum of 4 quarters · filed 2026-08-12
2026-03-31$1.92M
10-Q · filed 2026-05-06
$3.48M
derived: sum of 2 quarters · filed 2026-05-06
$4.99M
derived: sum of 3 quarters · filed 2026-05-06
$7.03M
derived: sum of 4 quarters · filed 2026-08-12
2025-12-31$1.55M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-18
$3.07M
derived: sum of 2 quarters · filed 2026-03-18
$5.11M
derived: sum of 3 quarters · filed 2026-08-12
$6.94M
10-K · filed 2026-03-18
2025-09-30$1.51M
10-Q · filed 2025-11-13
$3.56M
derived: sum of 2 quarters · filed 2026-08-12
$5.39M
10-Q · filed 2025-11-13
$7.87M
derived: sum of 4 quarters · filed 2026-08-12
2025-06-30$2.04M
10-Q · filed 2026-08-12
$3.88M
10-Q · filed 2026-08-12
$6.36M
derived: sum of 3 quarters · filed 2026-08-12
$8.12M
derived: sum of 4 quarters · filed 2026-08-12
2025-03-31$1.83M
10-Q · filed 2026-05-06
$4.32M
derived: sum of 2 quarters · filed 2026-05-06
$6.08M
derived: sum of 3 quarters · filed 2026-05-06
$7.56M
derived: sum of 4 quarters · filed 2026-05-06
2024-12-31$2.48M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-18
$4.25M
derived: sum of 2 quarters · filed 2026-03-18
$5.73M
derived: sum of 3 quarters · filed 2026-03-18
$7.58M
10-K · filed 2026-03-18
2024-09-30$1.76M
10-Q · filed 2025-11-13
$3.24M
derived: sum of 2 quarters · filed 2025-11-13
$5.10M
10-Q · filed 2025-11-13
2024-06-30$1.48M
10-Q · filed 2025-08-06
$3.33M
10-Q · filed 2025-08-06
2024-03-31$1.85M
10-Q · filed 2025-05-07
2023-12-31$5.01M
10-K · filed 2025-03-19

Similar stocks

Stock NameCountryMarket CapPE Ratio
AMERICAN SHARED HOSPITAL SERVICES (AMS)United States$0.010B-5.64
Advanced Biomed Inc. (ADVB)$0.009B
Aclarion, Inc. (ACON)United States$0.008B
BioNexus Gene Lab Corp (BGLC)$0.004B
Freenome, Inc. (FRNM)United States$0.143B
EXAGEN INC. (XGN)United States$0.212B-5.95
BIODESIX INC (BDSX)United States$0.312B
Fulgent Genetics, Inc. (FLGT)United States$0.593B-6.70
Lumexa Imaging Holdings, Inc. (LMRI)United States$0.951B
CASTLE BIOSCIENCES INC (CSTL)United States$1.074B-37.45